Background: Psoriasis is an immune-mediated, inflammatory disease. Adipokines contribute to the regulation of immune-mediated processes and inflammation. Objective: The aim of our study was to systematically review the literature for studies that have evaluated the circulating concentrations of adipokines in patients with psoriasis and controls and to meta-analyze the best evidence available. Methods: Eligible were studies that have assessed leptin, resistin, or adiponectin concentrations in psoriatic patients and a reference group. The study was conducted in adherence with the PRISMA standards. Results: Psoriatic patients had higher leptin concentrations compared to controls (random effects model, mean difference, MD = 5.64 ng/mL, 95% CI: 3.00-8.29, p < 0.0001). Heterogeneity among studies was high (I2 = 95.9%). Psoriatic patients had higher resistin concentrations compared to controls (MD = 4.66 ng/mL, 95% CI: 2.62-6.69, p < 0.0001). Heterogeneity was high (I2 = 99.2%). Finally, psoriatic patients had lower adiponectin concentrations compared to controls (MD = -1.87 μg/mL, 95% CI: -2.76 to -0.98, p < 0.0001). Heterogeneity was high (I2 = 95.9%). Conclusion: The study supported the hypothesis that leptin and resistin concentrations are higher and adiponectin concentrations are lower in patients with psoriasis compared to controls. Hereby, the suggested pathogenic link between psoriasis and metabolic syndrome/obesity is reinforced and the role of comorbidities in psoriasis is highlighted.

Keywords:
Leptin, Resistin, Adiponectin, Psoriasis, Adipokines, Meta-analysis
1.
Warnecke C, Manousaridis I, Herr R, et al: Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case control study. Eur J Dermatol 2011;21:761-770.
2.
Perera GK, Di Meglio P, Nestle FO: Psoriasis. Annu Rev Pathol 2012;7:385-422.
3.
Blauvelt A: T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008;128:1064-1067.
4.
Griffiths CE, Barker JN: Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-271.
5.
Schon MP , Boehncke WH: Psoriasis. N Engl J Med 2005;352:1899-1912.
6.
Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al: Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009;129:79-88.
7.
Michalak-Stoma A, Pietrzak A, Szepietowski JC, Zalewska-Janowska A, Paszkowski T, Chodorowska G: Cytokine network in psoriasis revisited. Eur Cytokine Netw 2011;22:160-168.
8.
Axelsson J, Heimburger O, Lindholm B, Stenvinkel P: Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 2005;15:131-136.
9.
Huang H, Shen E, Tang S, et al: Increased serum resistin levels correlate with psoriasis: a meta-analysis. Lipids Health Dis 2015;14:44.
10.
Zhu KJ, Shi G, Zhang C, Li M, Zhu CY, Fan YM: Adiponectin levels in patients with psoriasis: a meta-analysis. J Dermatol 2013;40:438-442.
11.
Zhu KJ, Zhang C, Li M, Zhu CY, Shi G, Fan YM: Leptin levels in patients with psoriasis: a meta-analysis. Clin Exp Dermatol 2013;38:478-483.
12.
Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y: Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev 2014;13:981-1000.
13.
Fantuzzi G: Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-919; quiz 920.
14.
Abdel Hay RM, Rashed LA: Association between the leptin gene 2548G/A polymorphism, the plasma leptin and the metabolic syndrome with psoriasis. Exp Dermatol 2011;20:715-719.
15.
Akcali C, Buyukcelik B, Kirtak N, Inaloz S: Clinical and laboratory parameters associated with metabolic syndrome in Turkish patients with psoriasis. ISRN Dermatol 2014;42:386-394.
16.
Asha K, Sharma SB, Singal A, Aggarwal A: Association of carotid intima-media thickness with leptin and apoliprotein B/apoliprotein A-I ratio reveals imminent predictors of subclinical atherosclerosis in psoriasis patients. Acta Medica (Hradec Kralove) 2014;57:21-27.
17.
Baran A, Flisiak I, Jaroszewicz J, Swiderska M: Serum adiponectin and leptin levels in psoriatic patients according to topical treatment. J Dermatolog Treat 2015;26:134-138.
18.
Campanati A, Ganzetti G, Giuliodori K, et al: Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: results of a retrospective analysis. Int J Dermatol 2015;54:839-845.
19.
Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbasi MO, Ergun T: Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008;159:820-826.
20.
Chen YJ, Wu CY, Shen JL, et al: Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008;144:1571-1575.
21.
Coban M, Tasli L, Turgut S, Ozkan S, Tunc Ata M, Akin F: Association of adipokines, insulin resistance, hypertension and dyslipidemia in patients with psoriasis vulgaris. Ann Dermatol 2016;28:74-79.
22.
Coimbra S, Oliveira H, Reis F, et al: Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci 2009;55:202-204.
23.
Coimbra S, Oliveira H, Reis F, et al: Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study. Am J Clin Dermatol 2010;11:423-432.
24.
Coimbra S, Oliveira H, Reis F, et al: Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol 2010;24:1386-1394.
25.
Corbetta S, Angioni R, Cattaneo A, Beck-Peccoz P, Spada A: Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 2006;154:83-86.
26.
Enany B, El Zohiery AK, Elhilaly R, Badr T: Carotid intima-media thickness and serum leptin in psoriasis. Herz 2012;37:527-533.
27.
Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U: Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis? Exp Dermatol 2012;21:43-47.
28.
Gisondi P, Lora V, Bonauguri C, Russo A, Lippi G, Girolomoni G: Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br J Dermatol 2013;168:749-755.
29.
Johnston A, Arnadottir S, Gudjonsson JE, et al: Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008;159:342-350.
30.
Kadry D, Hegazy RA ,Rashed L: Osteopontin and adiponectin: how far are they related in the complexity of psoriasis? Arch Dermatol Res 2013;305:939-944.
31.
Karadag AS, Ertugrul DT, Kalkan G, et al: The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: a noncontrolled study. Dermatology 2013;227:103-108.
32.
Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M: Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008;159:1364-1367.
33.
Kaur S, Zilmer K, Leping V, Zilmer M: The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis. J Eur Acad Dermatol Venereol 2011;25:1328-1333.
34.
Kawashima K, Torii K, Furuhashi T, et al: Phototherapy reduces serum resistin levels in psoriasis patients. Photodermatol Photoimmunol Photomed 2011;27:152-155.
35.
Kondelkova K, Borska L, Andrys C, et al: Selected inflammatory and metabolic markers in psoriatic patients treated with Goeckerman therapy. Mediators Inflamm 2015;2015:979526.
36.
Li RC, Krishnamoorthy P, DerOhannessian S, et al: Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clin Exp Dermatol 2014;39:19-24.
37.
Lora V, Bonaguri C, Gisondi P, et al: Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. Immunol Res 2013;56:382-389.
38.
Madanagobalane S, Sandhya V, Anandan S, Seshadri KG: Circulating adiponectin levels in Indian patients with psoriasis and its relation to metabolic syndrome. Indian J Endocrinol Metab 2014;18:191-196.
39.
Mitsuyama S, Abe F, Kimura M, Yoshida M, Higuchi T: Association between leptin gene expression in subcutaneous adipose tissue and circulating leptin levels in obese patients with psoriasis. Arch Dermatol Res 2015;307:539-544.
40.
Nakajima H, Nakajima K, Tarutani M, Morishige R, Sano S: Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients. Arch Dermatol Res 2011;303:451-455.
41.
Oh YJ, Lim HK: Serum leptin and adiponectin levels in Korean patients with psoriasis. J Korean Med Sci 2014;29:729-734.
42.
Ozdemir M, Yuksel M, Gokbel H, Okudan N, Mevlitoglu I: Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin. J Dermatol 2012;39:443-448.
43.
Rajappa M, Rathika S, Munisamy M, Chandrashekar L, Thappa DM: Effect of treatment with methotrexate and coal tar on adipokine levels and indices of insulin resistance and sensitivity in patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2015;29:69-76.
44.
Robati RM, Partovi-Kia M, Haghighatkhah HR, Younespour S, Abdollahimajd F: Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis: is psoriasis associated with atherosclerosis? J Am Acad Dermatol 2014;71:642-648.
45.
Romani J, Caixas A, Ceperuelo-Mallafre V, et al: Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI. Arch Dermatol Res 2013;305:105-112.
46.
Senturk N, Aydin F, Birinci A, et al: Investigation for the leptin 1 and LEP G2548A gene polymorphism in psoriasis. Eur J Dermatol 2008;18:343-344.
47.
Sereflican B, Goksugur N, Bugdayci G, Polat M, Haydar Parlak A: Serum visfatin, adiponectin, and tumor necrosis factor alpha (TNF-α) levels in patients with psoriasis and their correlation with disease severity. Acta Dermatovenerol Croat 2016;24:13-19.
48.
Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K: Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 2009;55:62-63.
49.
Takahashi H, Tsuji H, Honma M, Ishida-Yamamoto A, Iizuka H: Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Arch Dermatol Res 2013;305:113-116.
50.
Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen HD: Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008;158:1134-1135.
51.
Xue Y, Jiang L, Cheng Q, et al: Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One 2012;7:e46740.
52.
Viswanathan M, Berkman ND, Dryden DM, Hartling L: AHRQ Methods for Effective Health Care. Assessing Risk of Bias and Confounding in Observational Studies of Interventions or Exposures: Further Development of the RTI Item Bank. Rockville, Agency for Healthcare Research and Quality, 2013.
53.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
54.
Egger M, Davey Smith G, Altman D: Systematic Reviews in Health Care: Meta-Analysis in Context. London, BMJ, 2001.
55.
Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
56.
Wolk K, Sabat R: Adipokines in psoriasis: An important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord 2016;17:305-317.
57.
Boehncke WH, Gladman DD, Chandran V: Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting. J Rheumatol 2011;38:567-571.
58.
Naldi L, Addis A, Chimenti S, et al: Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 2008;217:365-373.
59.
Upala S, Sanguankeo A: Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. Int J Obes (Lond) 2015;39:1197-1202.
60.
Curat CA, Wegner V, Sengenes C, et al: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006;49:744-747.
61.
Winer S, Winer DA: The adaptive immune system as a fundamental regulator of adipose tissue inflammation and insulin resistance. Immunol Cell Biol 2012;90:755-762.
62.
Nakajima H, Nakajima K, Tarutani M, Sano S: Clear association between serum levels of adipokines and T-helper 17-related cytokines in patients with psoriasis. Clin Exp Dermatol 2013;38:66-70.
63.
Bahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arikan S: The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults? J Endocrinol Invest 2007;30:210-214.
64.
Sterry W, Strober BE, Menter A: Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007;157:649-655.
65.
Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H: Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008;159:1207-1208.
66.
Hulthe J, Hulten LM, Fagerberg B: Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 2003;52:1612-1614.
67.
Spranger J, Kroke A, Mohlig M, et al: Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361:226-228.
68.
Coimbra S, Catarino C, Santos-Silva A: The triad psoriasis-obesity-adipokine profile. J Eur Acad Dermatol Venereol 2016;30:1876-1885.
69.
Boehncke WH, Boehncke S, Tobin AM, Kirby B: The “psoriatic march”: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011;20:303-307.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.